收费全文 | 997389篇 |
免费 | 76841篇 |
国内免费 | 2619篇 |
耳鼻咽喉 | 12993篇 |
儿科学 | 34537篇 |
妇产科学 | 28505篇 |
基础医学 | 145376篇 |
口腔科学 | 27801篇 |
临床医学 | 90408篇 |
内科学 | 193896篇 |
皮肤病学 | 22963篇 |
神经病学 | 79168篇 |
特种医学 | 38488篇 |
外国民族医学 | 305篇 |
外科学 | 149838篇 |
综合类 | 23757篇 |
一般理论 | 385篇 |
预防医学 | 77865篇 |
眼科学 | 22643篇 |
药学 | 71899篇 |
3篇 | |
中国医学 | 2031篇 |
肿瘤学 | 53988篇 |
2018年 | 10594篇 |
2017年 | 8261篇 |
2016年 | 9417篇 |
2015年 | 10644篇 |
2014年 | 14490篇 |
2013年 | 22064篇 |
2012年 | 29102篇 |
2011年 | 30956篇 |
2010年 | 18557篇 |
2009年 | 17497篇 |
2008年 | 28894篇 |
2007年 | 30572篇 |
2006年 | 31059篇 |
2005年 | 29738篇 |
2004年 | 29019篇 |
2003年 | 27855篇 |
2002年 | 26870篇 |
2001年 | 46953篇 |
2000年 | 48057篇 |
1999年 | 40283篇 |
1998年 | 11188篇 |
1997年 | 10104篇 |
1996年 | 10164篇 |
1995年 | 9780篇 |
1994年 | 9092篇 |
1993年 | 8484篇 |
1992年 | 32259篇 |
1991年 | 31465篇 |
1990年 | 31009篇 |
1989年 | 29877篇 |
1988年 | 27171篇 |
1987年 | 27331篇 |
1986年 | 25435篇 |
1985年 | 24604篇 |
1984年 | 18400篇 |
1983年 | 15518篇 |
1982年 | 9290篇 |
1981年 | 8376篇 |
1979年 | 16863篇 |
1978年 | 12220篇 |
1977年 | 10318篇 |
1976年 | 9758篇 |
1975年 | 10180篇 |
1974年 | 12321篇 |
1973年 | 11845篇 |
1972年 | 10887篇 |
1971年 | 10113篇 |
1970年 | 9375篇 |
1969年 | 8725篇 |
1968年 | 8104篇 |
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献Methods: Using the Schedule for Clinical Assessment in Neuropsychiatry, tedium vitae was assessed in 130 stroke survivors attending rehabilitation in a large Nigerian university hospital. Global cognitive and executive dysfunctions were evaluated, respectively, using the Mini Mental State Examination and the modi?ed Indiana University Token test. All participants had their index stroke 3 to 24 months before recruitment into the study. We also examined a comparative group of 130 age, gender, and education matched apparently normal persons who were unrelated to the stroke survivors. Associations were explored using univariate and multivariate logistic regression analyses.
Results: Tedium vitae was experienced by 16 (12.3%) stroke survivors compared with 5 (3.9%) in the comparative group (O. R = 3.5, 95% C. I = 1.3–9.9, p = 0.018). Among stroke survivors, those who were retired were more likely to experience tedium vitae (56.2%, p = 0.045). In analyses adjusting for the effect of systemic hypertension, cognitive dysfunction, retirement and marital separation, there was a 3.5-fold increase in the odds of experiencing tedium vitae after surviving a stroke (O. R = 3.5, 95% C. I = 1.1–11.6, p = 0.042).
Conclusions: Tedium vitae is a common suicidal experience after stroke and may be among the earliest perceptible pointer to impending poststroke suicide. It is easy to assess and may be less costly to obtain an adequate sample size in studies aiming to understand the phenomenon of suicide in the stroke population. 相似文献